NERVIANO MEDICAL SCIENCES ANNOUNCED CLINICAL TRIAL APPROVAL IN CHINA OF THE PARP INHIBITOR NMS-293 IN PATIENTS WITH ADVANCED SOLID TUMORS TODAY.
Nerviano Medical Science Srl, the NMS Group subsidiary specialized in research and development of innovative oncological drugs, today announced the recent approval of a phase I clinical study for its PARP inhibitor (NMS-03305293) by China National Medical Products...
DMED SUCCESSFULLY ASSISTED ITALIAN NMS GROUP’S PARP INHIBITOR TO OBTAIN CLINICAL TRIAL APPROVAL
Nerviano, 30.11.2020 dMed Company (Shanghai) Ltd. congratulated the recent approval of a PARP inhibitor (NMS-03305293 capsules) of its collaborator NMS Group, an Italian oncology drug discovery and development company, by the National Medical Products Administration...
NANDING ZHAO APPOINTED CEO OF NMS GROUP TO ACCELERATE THE DEVELOPMENT OF THE GROUP’S STRATEGY
Nerviano, 02.10.2020 NMS Group announces today that its board of directors has accepted the resignation of Ying Shao as CEO, effective October 1, 2020. The Board has contextually appointed as CEO Dr. Nanding Zhao. Dr. Nanding Zhao, PhD and MBA, is an executive leader...
ROZLYTREK, ROCHE’S FIRST TUMOUR-AGNOSTIC THERAPY, APPROVED IN EUROPE FOR PEOPLE WITH NTRK FUSION-POSITIVE SOLID TUMOURS AND FOR PEOPLE WITH ROS1-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
Basel, 03.08.2020 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid...
THERMO FISHER SCIENTIFIC SIGNS COMPANION DIAGNOSTIC AGREEMENT WITH CHUGAI PHARMACEUTICAL
Calif, 08.07.2020 Thermo Fisher Scientific has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, and has applied to the Ministry of Health, Labour and Welfare (MHLW) to expand the use of the Oncomine Dx...
CANCER PATIENTS TO BENEFIT FROM NEW HISTOLOGY INDEPENDENT TREATMENT
25.06.2020 Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF). As a histology independent treatment, entrectinib targets all solid...
CARDIFF ONCOLOGY DATA CONTINUES TO DEMONSTRATE EFFICACY, DURABILITY AND SAFETY OF ONVANSERTIB IN PATIENTS WITH DIFFICULT-TO-TREAT RELAPSED/REFRACTORY AML
San Diego, 15.06.2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate...
NICE APPROVES NEW RARE LUNG CANCER TREATMENT FROM ROCHE
15.06.2020 By Emma Morriss, Pharmafield The National Institute for Health and Care Excellence (NICE) has approved a new rare lung cancer treatment. NICE has published its decision to grant a positive final appraisal document (FAD) for the use of Roche’s Rozlytrek®▼...
CARDIFF ONCOLOGY ANNOUNCES EXPANDED ACCESS PROGRAM FOR ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER AS FOLLOW-ON TO FAST TRACK DESIGNATION
San Diego, 09.06.2020 For the full press release: https://cardiffoncology.investorroom.com/2020-06-09-Cardiff-Oncology-Announces-Expanded-Access-Program-for-Onvansertib-in-KRAS-Mutated-Metastatic-Colorectal-Cancer-as-Follow-On-to-Fast-Track-Designation
CHMP RECOMMENDS EU APPROVAL OF ROCHE’S ROZLYTREK® (ENTRECTINIB) FOR PEOPLE WITH NTRK FUSION-POSITIVE SOLID TUMOURS AND FOR PEOPLE WITH ROS1-POSITIVE, ADVANCED NON-SMALL CELL LUNG CANCER
Basel, 29.05.2020 Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under conditional marketing authorisation for...
Our Archive
